EFFICACY OF SULFADOXINE-PYRIMETHAMINE IN THE TREATMENT OF UNCOMPLICATED PLASMODIUM FALCIPARUM MALARIA IN EAST TIMOR | Zendy

Matthew Burns | Zendy; Joanne Baker | Zendy; Alyson Auliff | Zendy; Michelle L. Gatton | Zendy; Michael D. Edstein | Zendy; Jennifer M. Peters | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

EFFICACY OF SULFADOXINE-PYRIMETHAMINE IN THE TREATMENT OF UNCOMPLICATED PLASMODIUM FALCIPARUM MALARIA IN EAST TIMOR

Author(s) -

Matthew Burns,

Joanne Baker,

Alyson Auliff,

Michelle L. Gatton,

Michael D. Edstein,

Jennifer M. Peters

Publication year - 2006

Publication title -

american journal of tropical medicine and hygiene

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.015

H-Index - 151

eISSN - 1476-1645

pISSN - 0002-9637

DOI - 10.4269/ajtmh.2006.74.361

Subject(s) - sulfadoxine/pyrimethamine , gametocyte , malaria , plasmodium falciparum , genotyping , sulfadoxine , pyrimethamine , parasitemia , dihydrofolate reductase , medicine , biology , virology , immunology , genotype , genetics , gene , methotrexate

The efficacy of sulfadoxine-pyrimethamine (SP) in East Timor is unknown. We treated 38 individuals with uncomplicated Plasmodium falciparum malaria with SP and monitored the outcome for 28 days. Recrudescent parasitemia, confirmed by genotyping, were detected in three individuals resulting in a late treatment failure rate of 7.9% (95% confidence interval = 1.7-21.4%). The results suggest that SP is still efficacious in treating uncomplicated P. falciparum malaria in East Timor. However, the useful life of SP in East Timor may be limited because 80% of the parasites in our samples were found to already carry double mutations in P. falciparum dihydrofolate reductase (S108N/C59R). The data from this study also highlights that the presence of gametocytes may significantly influence the estimate of SP efficacy determined by genotyping.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research